ArticleScientific reports2025
Abnormal regional brain activity associated with relapse in early abstinent methamphetamine-dependent individuals.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Methamphetamine (MA) can cause functional abnormalities in the brain. However, the correlations between the abnormal brain activity and relapse in abstinent MA-dependent individuals (MADIs) were still unclear. This study aimed to explore the changes of regional brain activation associated with relapse in early abstinent MADIs, which could provide potential neuroimaging markers for predicting the relapse susceptibility. Twenty-seven individuals who relapsed to MA within 1 year after abstaining from MA, as well as 28 healthy controls (HCs), were enrolled in this study. Resting-state functional magnetic resonance imaging (rs-fMRI) collected from all HCs, and MADIs when they were abstinent from MA (Stage I) and relapsed to MA (Stage II). The measures for evaluating regional brain activity including regional homogeneity (ReHo) and fractional amplitude of low-frequency fluctuation (fALFF) were calculated for all participants. ReHo and fALFF values were compared between MADIs at Stage I, Stage II and HCs. Finally, relationships between altered brain regions and duration of MA use, duration of relapse were evaluated by Pearson correlation analysis. Compared with HCs, MADIs at Stage I demonstrated decreased brain activity in three cortical regions and increased brain activity in several subcortical regions, especially bilateral putamen. In addition, MADIs at Stage II exhibited a wider range of brain regions with abnormal activity, which presented as decreased activity mainly in the middle cingulate gyrus, parietal and occipital regions, and increased activity mostly in the subcortical regions (striatum, thalamus and hippocampal structure) and several prefrontal regions. Moreover, MADIs at Stage II showed decreased activity in the parietal regions and increased brain activity in the prefrontal and subcortical regions, especially bilateral caudate nucleus. The fALFF values of left and right caudate nucleus were negatively associated with duration of relapse. There were still abnormal activities in the brain of MADIs even when they were abstinent from MA. Increased activity in the bilateral putamen might be associated with early relapse in abstinent MADIs. Relapse to MA use could cause more wider range of abnormal brain activity, especially increased activity in the striatum, which might lead to more higher relapse rate of MA use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.